Glucocorticoids mediate transcriptome-wide alternative polyadenylation: Potential mechanistic and clinical implications

Thanh Thanh L. Nguyen1,2 | Duan Liu1 | Huanyao Gao1 | Zhenqing Ye4
Jeong-Heon Lee4 | Lixuan Wei1 | Jia Yu1 | Lingxin Zhang1 | Liewei Wang1
Tamas Ordog5,6 | Richard M. Weinshilboum1

1Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA
2Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, Minnesota, USA
3Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA
4Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA
5Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota, USA
6Division of Gastroenterology and Hepatology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA

Abstract

Alternative polyadenylation (APA) is a common genetic regulatory mechanism that generates distinct 3′ ends for RNA transcripts. Changes in APA have been associated with multiple biological processes and disease phenotypes. However, the role of hormones and their drug analogs in APA remains largely unknown. In this study, we investigated transcriptome-wide the impact of glucocorticoids on APA in 30 human B-lymphoblastoid cell lines. We found that glucocorticoids could regulate APA for a subset of genes, possibly by changing the expression of 142 RNA-binding proteins, some with known APA-regulating properties. Interestingly, genes with glucocorticoid-mediated APA were enriched in viral translation-related pathways, while genes with glucocorticoid-mediated expression were enriched in interferon and interleukin pathways, suggesting that glucocorticoid-mediated APA might result in functional consequences distinct from gene expression. For example, glucocorticoids, a pharmacotherapy for severe COVID-19, were found to change the APA but not the expression of LY6E, an important antiviral inhibitor in coronavirus diseases. Glucocorticoid-mediated APA was also cell-type-specific, suggesting an action of glucocorticoids that may be unique to immune regulation. We also observed evidence for genotype-dependent glucocorticoid-mediated APA (referred to as pharmacogenomic-alterative polyadenylation quantitative trait loci), providing potential functional mechanisms for a series of common genetic variants that had previously been associated with immune disorders, but without a clear mechanism. In summary, this study reports a series of observations regarding the impact of glucocorticoids on APA, raising the possibility that this mechanism might have implications for both disease pathophysiology and drug therapy.
INTRODUCTION

Alternative polyadenylation (APA) is a molecular regulatory mechanism that generates RNA isoforms with differential usage of polyadenylation sites (PASs). When APA takes place in the final exon of a gene, it creates RNA transcripts with differential lengths of the 3′-untranslated region (3′-UTR) of the gene. When APA takes place in introns, it can generate transcript variants with new 3′ ends, a process that often involves differential splicing. The functional outcomes of APA include modulation of mRNA stability and translation, mRNA localization, and, intriguingly, protein localization independent of mRNA localization. Even though it has not been as extensively studied as gene transcription, APA is a common phenomenon with at least 70% of mammalian mRNA-coding genes showing APA isoforms, suggesting that it is one of the major regulatory mechanisms of cellular and molecular dynamics with important functional consequences. In fact, dysregulation of APA has been associated with disease phenotypes including cancer, immunological, and neurological diseases.

In recent years, experimental methods and computational tools for detecting APA have developed rapidly, allowing the detection of transcriptome-wide APA events on a scale that was not possible previously. Of interest, there are now computational algorithms that enable detection of APA events directly from standard poly(A)-enriched RNA-seq data, allowing the generation of novel hypotheses and observations using existing RNA-seq datasets from large databases. For example, using DaPars, an algorithm that detects de novo PAS proximal to the last exon by modeling read counts of RNA-seq, investigators analyzed data from the Cancer Genome Atlas Project and observed a global shortening of 3′UTRs in tumors compared to normal tissue. A similar approach was also applied to analyze RNA-seq datasets generated by the Genotype-Tissue Expression (GTEx) project for the identification of global APA across different types of human tissues. Most interestingly, by integrating genome-wide single-nucleotide polymorphism (SNP) genotyping data with APA, investigators were able to discover quantitative trait loci associated with APA (3′aQTLs), many of which had been associated with disease phenotypes but with functions unexplained by expression QTLs (eQTLs). Several other biological processes have been reported to affect global APA including cell proliferation, cell differentiation, and viral infection. However, the effects on APA of hormones and their drug analogs, which have mainly been studied for their effects on gene transcription and expression, remain largely unknown with the exception of a case report for estrogens. In the present study, we systematically characterized transcriptome-wide the role of glucocorticoids, a major class of hormones, in the regulation of APA.

Clinically, glucocorticoids represent a class of medication used to treat a variety of inflammatory and autoimmune diseases. While the role of glucocorticoids in activating the glucocorticoid receptor (GR) to become a transcription factor has been well-characterized, to our knowledge there have been no studies of their regulation of APA. To characterize transcriptome-wide glucocorticoid-dependent APA, we analyzed 90 standard RNA-seq datasets that we had generated from 30 human B-lymphoblastoid cell lines (LCLs) before and after glucocorticoid treatment. We discovered a group of immune-specific genes with glucocorticoid-mediated APA that appeared to be

---

Study Highlights

**WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?**
Polyadenylation is an important cellular regulatory mechanism. The impact of glucocorticoids, drugs and hormones that play a role in a wide range of diseases, on alternative polyadenylation is not known.

**WHAT QUESTION DID THIS STUDY ADDRESS?**
We set out to ask whether glucocorticoids might alter polyadenylation transcriptome-wide and, if so, what the potential mechanism and clinical implications might be.

**WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?**
This study demonstrates that glucocorticoids can have profound transcriptome-wide effects on polyadenylation, effects with potential downstream implications for disease pathophysiology and for pharmacogenomic variation in drug response.

**HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?**
This study opens a new area for the application of pharmacogenomic techniques and provides novel perspectives for the study of mechanism of therapeutic response.
functionally distinct from those with glucocorticoid-mediated alterations in expression. We observed that one possible mechanism underlying glucocorticoid-mediated APA involved GR-dependent regulation of RNA-binding proteins (RBP), an important group of APA regulators. We also uncovered non-coding genetic risk sequence variants that potentially behaved as alternative polyadenylation quantitative trait loci (3′aQTL), but only after glucocorticoid exposure, some of which had previously been associated with glucocorticoid-related disease phenotypes during genome/phenome-wide association studies.

**METHODS**

See Supplementary Methods for citations of bioinformatic packages and tools.

**Generation of a 300 LCL genomic panel**

Three hundred lymphoblastoid cell lines were obtained from the Coriell Institute and were genotyped with the Illumina HumanHap550K and HumanExon510S-Duo Bead Chips in our laboratory, information that was combined with data generated at the Coriell Institute using the Affymetrix Human SNP Array 6.0. The genotype data were deposited in the National Center for Biotechnology Information Gene Expression Omnibus under accession number GSE23120.

**Identification of APA events from RNA-seq data**

Thirty LCLs with similar levels of GR expression selected from the 300-LCL panel were exposed to cortisol, an endogenous GR ligand, followed by the addition of CORT108297 (C297), a selective GR modulator that could antagonize cortisol activity for 9 h. RNA-seq for these samples were obtained as described previously. The RNA seq data were deposited in the National Center for Biotechnology Information Gene Expression Omnibus under accession number GSE185941.

**Identification of differentially expressed genes (DEGs) from RNA-seq**

Raw counts were generated from the RNA-seq bam files with the Python package “HTseq” and differential expression analysis was conducted with the R package “EdgeR”. Only genes that passed counts per million mapped reads of 32 were included in the analysis. Pathway analysis was conducted with EnrichR both for genes with glucocorticoid-mediated APA and genes with glucocorticoid-mediated expression. Available bed files for cortisol-regulated RBPs were then downloaded from the Encyclopedia of DNA Elements (ENCODE) Project. The binding sites of these RBPs were overlapped with 3′UTR data containing the cortisol-mediated APA sites for each gene using bedtools.

**Cell culture and drug treatment during validation experiments for glucocorticoid-mediated APA observed for the gene LY6E**

LCL GM17268 was cultured in RPMI 1640 supplemented with 15% FBS and 1% penicillin/streptomycin. Prior
to glucocorticoid treatment experiments, all cells were grown in 5% charcoal-stripped media for 48 h. The cells were then treated with: (1) vehicle (dimethyl sulfoxide [DMSO] 0.1% and ethanol 0.1%), (2) hydrocortisone 100 nM (Sigma-Aldrich, dissolved in ethanol) plus DMSO 0.1%; or (1) vehicle, and 100 nM dexamethasone (Sigma-Aldrich, water soluble). Treatment time was optimized to achieve the greatest observed effect of glucocorticoid on APA at 3, 6, 9, and 12 h (data not shown). Since cortisol-induced APA changes were most striking at 9 h, we repeated the experiments with different dosages of the drugs, specifically, 0, 1, 10, 100, and 1000 nM after 9 h of incubation.

**cDNA synthesis**

The cells were pelleted and harvested for RNA extraction. Total RNA was extracted with the Quick-RNA Miniprep kit (Zymo, Cat# R1055) per the manufacturer’s instructions. A total of 2 μg of total RNA was used for cDNA synthesis using the SuperScript™ III First-Strand Synthesis System (Thermo Fisher, Cat# 18080-093) and poly(A) oligo(dT)20 (Thermo Fisher, Cat# 18418020) per the manufacturer’s instruction. Briefly, a mixture of 1 μl of oligo(dT)20 (50 μM), 1 μl of 10 mM dNTP mix (Thermo Fisher, Cat# 18427088), 2 μg of total RNA, and distilled water to 13 μl was heated to 65°C for 5 min and incubated on ice for 1 min. This step was followed by the addition of 4 μl 5X First-Strand Buffer, 1 μl 0.1 M DTT, 1 μl RNAse Inhibitor (Cat# 10777-019, 40 units/μl), and 1 μl of SuperScript™ III reverse transcriptase (200 units/μl). This mixture was then incubated at 25°C for 5 min, 50°C for 45 min, and 70°C for 15 min. For removal of RNA complementary to the cDNA, 1 μl of RNase H (Ambion, Cat# AM2293) was incubated with the mixture at 37°C for 20 min. The cDNA was then ready for the PCR step.

**Quantitative reverse transcription polymerase chain reaction (qRT-PCR)**

Primer sequences targeting the predicted APA site in *LY6E* were designed using Primer3 software. The following two primers were used to perform this experiment: LY6E_3UTR_1 Forward: ACAGCCTGACCAAGACCTGT, Reverse CGCACCTGAAATTGCACAGAA, and LY6E_3UTR_2 Forward: FAATGTTGGTGTGGCTTCCAT, Reverse CAGCAGGCTCAGCAG. The product from the cDNA synthesis experiment was diluted 200 times before qRT-PCR, and the primers were diluted to a final concentration of 0.4 μM. Reaction for qRT-PCR was performed using Power SYBR™ Green PCR Master Mix (Cat# 43-676-59, Applied Biosystems Inc.). Analysis of qRT-PCR data was conducted using the 2−ΔΔCT method.

**Analysis of glucocorticoid-mediated alternative polyadenylation quantitative trait loci**

Some 1.3 million genotyped SNPs were filtered based on Hardy–Weinberg equilibrium (p > 0.001) with genotyping call rates of more than 95% and minor allelic frequencies of 0.18 or greater. All SNPs which had only one or two cell lines with homozygous variant genotypes among the 30 cell lines studied were excluded from further study. PDU1 for all treatment conditions were normalized to vehicle by genotypes, thus canceling out genotype effects at baseline. APA events without adequate coverage in more than one-third of the 30 LCLs and with no change in more than half of the 30 LCLs were excluded. Analysis of quantitative trait loci for delta PDU1 was conducted with the R package “Matrix eQTL” using ANOVA model. A total of 515,177,592 associations were conducted, and p-values with significant trends were defined as 5.16 × 10−8. Those SNPs were then overlapped with SNPs documented in the GWAS Catalog (https://www.ebi.ac.uk/gwas/) and with UK Biobank data (http://pheweb.sph.umich.edu/) for potentially significant clinical associations. Significant p-value cutoffs were defined by the databases queried.

**RESULTS**

**Glucocorticoids mediated global APA in human LCLs**

Thirty LCLs of differing genomic backgrounds were treated with vehicle, 100 nM cortisol (a GR agonist), and 100 nM cortisol plus 100 nM of CORT108297 (C297, a GR antagonist) to verify GR-dependent effect. Treatment conditions such as dose and incubation time were optimized before sequencing, and the treatment effect was confirmed for these datasets by expression quantification of prototypic GR-targeted genes such as *FKBP5* and *TSC22D3*. Specifically, the mRNA levels for *FKBP5* were increased by cortisol 5.5-fold (FDR = 1.41−41) and for *TSC22D3* 8.7-fold (FDR = 1.41−41). Their expression changes were then reduced by the GR antagonist C297 to 2.3-fold over control (FDR = 1.37−17) for *FKBP5* and 3.5-fold over control (FDR = 3.19−23) for *TSC22D3*. We then analyzed these 90 RNA-seq datasets to identify transcriptome-wide APA events using the computational algorithm DaPars v.2.0. DaPars gave an output of the percentage of PDU1 for each gene transcript, together with the position of the predicted PAS. A higher value for PDU1 corresponded to a
higher percentage of transcripts with longer 3’UTRs or more distal PAS. After PDU1 values were obtained for each gene in each sample, a total of 696 genes that displayed APA had been detected. Of these 696 genes, we found that cortisol regulated APA dynamics for 54 genes (Figure 1a, Table S1) (two-sided Wilcoxon matched-pair signed rank test; FDR < 0.05 across 30 LCLs). Importantly, those cortisol-mediated changes in APA were reversed after C297, that is, after antagonist treatment, confirming that the observed APA changes were dependent on glucocorticoid treatment. For example, cortisol decreased the percentage of distal PAS usage by 30% for LY6E mRNA, a gene that encodes lymphocyte antigen 6 family member E which plays a critical antiviral role in coronavirus diseases including SARS-CoV-2.25–28 This regulation resulted in a shortening of the LY6E 3’-UTR (Figure 1b). The addition of C297 reversed this cortisol-mediated repression back to baseline (Figure 1b,c). Interestingly, we found that cortisol treatment did not change LY6E mRNA levels in our LCLs but that it did mediate 3’-UTR APA to reduce the percentage of transcripts with long 3’UTRs (Figure 1b).

To validate the glucocorticoid-mediated APA observations for LY6E, we quantified the long LY6E 3’-UTR transcripts by qRT-PCR using two different sets of primers targeting the LY6E 3’-UTR region that covered the proximal PAS. We observed a dose-dependent repression by cortisol, and we replicated that dose-dependent regulation with dexamethasone, a potent synthetic glucocorticoid that is often used in the clinic (Figure 1d).

**Glucocorticoids mediated APA through transcriptional regulation of RNA-binding protein in human LCLs**

When we conducted pathway analysis of 1362 cortisol-responsive genes from our RNA-seq results (FDR < 0.05), we found that “RNA-binding protein” (RBP) was the most enriched pathway (adjusted p-value = 7.39E-04), raising the possibility that cortisol might regulate downstream RBPs with APA-regulating properties (Figure 2a). Therefore, we hypothesized that glucocorticoid-activated GR might regulate the expression of RBPs with known APA-regulating properties, which in turn might drive the changes observed for APA. From the pathway analysis, we observed that 142 proteins with RNA-binding properties were regulated by cortisol and that their cortisol-mediated expression was reversed by C297 (Figure 2b). To identify which of those 142 DEGs were directly regulated by GR, we consulted GR-targeted ChiP-seq and H3K27ac HiChIP datasets that we had previously generated in LCLs both with and without cortisol treatment, together with a 25-chromatin-state prediction model.20 We found that 27 (18%) of the 142 glucocorticoid-regulated RBPs had H3K27ac HiChIP loops that connected them with one or more cortisol-induced GR peaks, suggesting direct regulation through cortisol-mediated enhancers (Figure 2c,g, Table S2, Figure S1).

We then explored the function of the 142 cortisol-regulated RBPs by consulting enhanced crosslinking and immunoprecipitation sequencing (eCLIP-seq) datasets for more than 70 RBPs and their annotated functions that had been generated by the ENCODE project.24 We found that 12 of those cortisol-regulated RBPs had information for transcriptome-wide RNA-binding sites readily available in two human cell lines (Figure 2d; see Table S3 for specific ENCODE series numbers). Two of those 12 RBPs, EWSR1 and PABPN1, are known to bind to 3’UTRs and to regulate APA.29,30 Specifically, PABPN1 is known to suppress APA or prevent 3’UTR shortening,29 while EWSR1 is part of the FET RNA binding proteins family that can regulate APA depending on their binding sites.30 The other 10 cortisol-regulated RBPs such as CDC40, ZRANB2, DDX24, NKR, SF3B1, and NSUN2 are known to play diverse roles in RNA processing,31–36 but their roles—if any—in the regulation of APAs have yet to be determined.

When we integrated the eCLIP-seq data for the APA-regulating RBPs PABPN1 and EWSR1, as described earlier, with our APA analysis, we found that 68% of 54 genes with GR-mediated APA events were bound by either EWSR1 or PABPN1 at 3’UTRs containing the alternative PAS (Figure 2e). For example, based on eCLIP-seq data, EWSR1 bound to multiple sites in the LY6E 3’-UTR surrounding the predicted proximal PAS (Figure 2f). EWSR1 was downregulated by cortisol via
a cortisol-induced GR enhancer that loops across 100 kb to the EWSR1 promoter (Figure 2g), possibly causing the observed repression of the distal PAS usage. Taken together, these observations supported our hypothesis that glucocorticoids can mediate APA, at least in part, through the transcriptional regulation of RBPs with APA-regulating properties.

Glucocorticoid receptor is known to act as an RBP itself. However, a previous study reported that, in general, GR binds to the 5'UTR rather than the 3'UTR of
mRNAs and that GR-RNA binding is independent of AU-rich elements, an RNA-binding motif that is often found in 3′UTRs. This observation suggests that the RNA-binding property of GR might have limited effect on the glucocorticoid-dependent APA that we observed.

**Genes differentially expressed and genes alternatively polyadenylated by glucocorticoids are functionally distinct**

As described earlier, we identified 54 glucocorticoid-mediated APA genes, a much smaller number than the 1362 glucocorticoid-mediated DEGs in these same LCLs. Furthermore, we noticed that only 5 of those 54 APA genes overlapped with the 1362 DEGs (Figure 3a). Therefore, we asked what the function(s) of the glucocorticoid-mediated APA genes might be and how they might differ from those of the glucocorticoid-mediated DEGs. It is well known that one of the mechanisms underlying the immunosuppressant actions of glucocorticoids is mediated through the inhibition of interleukin and cytokine signaling pathways.

For example, glucocorticoids induce the expression of glucocorticoid-induced leucine zipper (GILZ, or TSC22D3), an inhibitor of NF-κB, and they inhibit the expression of pro-inflammatory cytokines and chemokines. We observed similar effects of cortisol in our LCLs, as demonstrated by pathway analysis of cortisol-mediated DEGs (Figure 3b, Table S4). However, we found that genes which displayed glucocorticoid-mediated APA were primarily enriched in viral translation-related pathways, with p-values more significant than those for pathways enriched for cortisol-mediated DEGs despite a smaller number of this class of genes (Figure 3c,d). That observation was consistent with previous studies which demonstrated that APA can play a crucial role in antiviral immune response. Indeed, LY6E, a gene showcased in previous paragraphs, represented an example of a glucocorticoid-mediated APA gene with emerging roles in a wide spectrum of viral diseases. Specifically, LY6E encodes a glycosyl-phosphatidyl-inositol-anchored cell surface protein that plays an important role in immunological regulation including modulation of viral infection by coronaviruses such as SARS-CoV-2. Specifically, LY6E has been shown to be an antiviral immune effector by interfering with spike protein-mediated membrane fusion, protecting a variety of cell types including primary B cells from coronavirus infection.

**Glucocorticoid-mediated APA is cell-type specific**

To determine whether the glucocorticoid-mediated APA effects that we observed in LCLs might apply to other types of cells, we analyzed published RNA-seq datasets from the ENCODE portal generated for A549 lung carcinoma epithelial cells before and after 100 nM dexamethasone treatment for 12 h, a treatment condition comparable to that used in our LCL study. Using similar analytical approaches to those which we applied for LCLs, we identified 2448 DEGs after dexamethasone treatment of A549 cells (FDR < 0.05), with 243 genes overlapping with DEGs that we had identified in LCLs (see Figure 4a). Interestingly, the most significant pathway enriched for glucocorticoid-regulated DEGs in A549 cells was the DNA-binding pathway (adjusted p-value = 3.022E-8) (Figure 4b), in contrast to the RNA-binding pathways observed in LCLs, as described earlier (Figure 2a). Using the DaPars v2.0 algorithm, we were able to detect 460 genes with APA events at baseline in A549 cells, genes which overlapped with 56% of the genes with APA that we had detected in LCLs (see Figure 4c). However, we did not detect any change in APA events after the dexamethasone treatment of A549 cells (FDR < 0.05; Figure 4d).
Consistent with these observations, many fewer RNA-binding-related genes were differentially expressed in A549 cells than in LCLs (21 vs. 142 genes) after glucocorticoid treatment (Figure 4a). Importantly, two genes with known APA-regulating properties and which explained 68% of glucocorticoid-dependent APA observed in LCLs, PABPN1 and EWSR1 (Figure 2e), were not differentially expressed in A549 cells after glucocorticoid treatment (Figure 4a). This result might explain why no glucocorticoid-mediated APA events were detected in A549 cells. These observations suggest that GR-mediated APA regulation may be highly cell-type specific and that it
may occur more often in association with immune-related functions of GR.

**Glucocorticoid-mediated APA in a genotype-dependent manner: association with clinical phenotypes**

Taking advantage of the genome-wide genotype data that we had already generated for our 30 LCLs, we asked whether SNPs might contribute to the observed variation in glucocorticoid-mediated APA. The fact that APA regulation at baseline can be genotype-dependent had already been demonstrated by other investigators based on the concept of 3’UTR alternative polyadenylation quantitative trait loci (3’aQTLs).\(^{14,41}\) Utilizing the GTEx database, Li et al.\(^{14}\) had observed that 3’aQTLs could potentially explain approximately 16.1% of currently known trait/disease-associated genetic variants. Acknowledging that 30 LCLs provided us with limited power, we undertook an exploratory search to identify evidence that SNP loci could be associated with glucocorticoid-mediated APA events, referred to hereafter as glucocorticoid-mediated pharmacogenomic-3’aQTLs (PGx-3’aQTLs). We then explored the possible link of those PGx-3’aQTLs to genetic variants that had been associated with clinical phenotypes. With the 30 LCLs used in this study, we were able to re-capture a series of previously identified

---

**FIGURE 3** Glucocorticoid-mediated alternative polyadenylation (APA) is functionally distinct from glucocorticoid-mediated gene expression. (a) Overlap of genes with cortisol-mediated APA and cortisol-mediated differentially expressed genes (DEGs) in the human B-lymphoblastoid cell lines (LCLs) that were studied. (b,c) Selected top pathways for genes with cortisol-mediated APA and DEGs in LCLs according to the KEGG 2021 and Bioplanet 2019 databases from the EnrichR server. (d) Specific cortisol-mediated APA genes enriched in pathways depicted in (b)
3′aQTL SNPs, such as SNPs in tight linkage disequilibrium ($r^2 > 0.70$) with rs10954213, a SNP that was associated with APA for the IRF5 3′UTR \(^9,14\) ($p = 4.69 \times 10^{-8}$; Figure 5a).

To identify possible glucocorticoid-mediated PGx-3′aQTL associations, we associated SNP genotypes with changes in percentage of distal APA usage between glucocorticoid treatment and vehicle exposure across our 30 LCLs (see Methods). That step identified a total of 66 cortisol-dependent candidate PGx-3′aQTLs ($p < 5.16 \times 10^{-8}$), all of which no longer exhibited SNP-APA change associations after the addition of the GR antagonist, C297 ($p \geq 0.05$), demonstrating a cortisol-dependent effect (Figure 5b, Table S5). To investigate whether these glucocorticoid-dependent PGx-3′aQTLs could potentially explain the function of SNPs previously associated with clinical phenotypes but with unclear functional mechanisms, we overlapped PGx-3′aQTL SNPs with those already reported to be genome-wide significant signals in the GWAS Catalog \(^42\) and/or the UK Biobank PheWAS Catalog. \(^43\) We found that five of our PGx-3′aQTLs had been associated with disease phenotypes (Figure 5c), four of which were related to known effects of glucocorticoid usage such as bacterial infections, \(^44\) inflammatory bowel disease, \(^45\) and cardiovascular disease. \(^46\) Furthermore, the function of the genes modulated by the PGx-3′aQTL appeared to be related to these associated phenotypes. For example, rs770150 was associated with bacterial enteritis based on PheWAS ($p = 4.7 \times 10^{-5}$), and it was found in our study to be a PGx-3′aQTL for DDX3X. Specifically, cortisol decreased PDUI in subjects with the AA genotypes but not subjects with other genotypes at this locus, and this repression was reversed by C297 (Figure 5d). DDX3X encodes a RBP that is known to play a critical role in antimicrobial innate immunity. \(^47,48\)

Another example involved rs2483280, a SNP previously associated by GWAS with electrocardiographic QRS duration ($2.0 \times 10^{-11}$). That SNP was associated with repressed PDUI for CCR7 in a genotype- and drug-dependent manner (Figure 5e). CCR7 encodes a chemokine receptor that has been shown to play a role in cardiac function. \(^49\) While these associations with disease through possible glucocorticoid-dependent mechanisms are intriguing, these SNPs did not disrupt GR binding sites and appeared to act through trans mechanisms that remain to be determined and validated in future studies with larger sample sizes.

**DISCUSSION**

Our study has provided a series of observations regarding the impact of glucocorticoids on alternative polyadenylation which, to our knowledge, had not been reported...
previously. In the clinic, glucocorticoids are used to treat a variety of inflammatory and autoimmune diseases. Traditional understanding of glucocorticoid mechanisms in immune regulation has been based on their activation of the glucocorticoid receptor (GR), which is then translocated to the nucleus where it binds to DNA to initiate gene transcription. We demonstrated that glucocorticoids could also regulate global APA for immune-related genes in human LCLs (Figure 1), genes that were functionally distinct from those influenced by glucocorticoids on expression level (Figure 3). Even though the number of glucocorticoid-dependent APA genes was smaller than that of glucocorticoid-dependent DEGs, glucocorticoid-dependent APA genes were highly enriched in “viral infection-related” pathways (Figure 3c), indicating a more specific function for glucocorticoid-dependent APA.

Characterization of glucocorticoid-dependent APA in viral infection might help us better understand the mechanism
of glucocorticoids’ therapeutic effects in diseases such as COVID-19,20 especially in light of our discovery that one of the most important antiviral genes in coronavirus diseases, LY6E,25–28 has its APA regulated by glucocorticoids.

Glucocorticoids are known to play important functional roles in a variety of physiological processes and diseases.19 However, the therapeutic usage of glucocorticoids remains largely dependent on their function in immunosuppression. Of interest, glucocorticoid-dependent APA, which possibly occurs through glucocorticoid-mediated transcriptional regulation of RBPs with APA-regulating properties (Figure 2), appears to be cell-type specific (Figure 4). Although comparable numbers of APA genes were identified in both LCLs and A549 lung cancer cells (Figure 4c), none of the glucocorticoid-dependent APA genes were identified in the A549 cell line (Figure 4d), raising the possibility that glucocorticoid-dependent APA could be more often immune-related. That possibility requires further investigation with more cell lines and tissue types, which, once confirmed, might expand our understanding of mechanism(s) for glucocorticoids’ immunosuppressive properties. However, the present study did not determine the functional consequences of these APA changes in terms of molecular and cellular dynamic changes induced by glucocorticoids. While mRNA stability is one of the known functional outcomes of APA,1 we found that glucocorticoid-mediated changes in APA were only associated with changes in gene expression in a small minority of DEGs in LCLs.

We also observed trends indicating that glucocorticoids could regulate APA in a genotype-dependent manner, a phenomenon that we referred to as “PGx-3′aQTL” (Figure 5). PGx-3′aQTLs could represent a novel type of context-dependent SNPs for which pharmacological or physiological reagents can “unmask” the function of silent non-coding SNPs with previously unknown functional roles. They could also potentially explain an aspect of gene × environment interaction in disease risk and variation in drug response that otherwise could not be explained by eQTLs or context-dependent eQTLs. Unlike diseases associated with glucocorticoid-mediated PGx-eQTLs which spanned a broad spectrum of glucocorticoid-related diseases as identified in our previous study,20 diseases or pathological states associated with glucocorticoid-mediated PGx-3′aQTLs appear to be limited to or focused on immune-related phenotypes—at least in LCLs. This observation is consistent with the fact that glucocorticoids regulate APA in a cell-type specific manner and appeared—in LCLs—to do so primarily for genes with immune-related functions. While these observations are intriguing, they clearly need to be validated with larger sample sizes.

In conclusion, our study has revealed a series of novel aspects of genomic regulation by glucocorticoids, particularly their impact on RNA polyadenylation with its possible role in disease risk and drug response variation, aspects that should be explored further for glucocorticoids and for other drugs that act through nuclear receptors.

AUTHOR CONTRIBUTIONS
T.T.L.N, D.L., and R.M.W. wrote the manuscript. T.T.L.N, D.L., R.M.W., L. Wang, T.O. and J.Y. designed the research. T.T.L.N., D.L., and L.Z. performed the research. T.T.L.N., H.G., D.L., Z.Y., and L. Wei analyzed the data. J.H.L., T.O., and L. Wang contributed new reagents/analytical tools.

ACKNOWLEDGMENT
We thank the ENCODE Consortium for their generation of the epigenomic datasets used in this study.

FUNDING INFORMATION
This work was supported by the U.S. National Institute of General Medical Sciences (Grant No. U19GM61388 to R.M.W. and L. Wang and R01GM28157 to R.M.W.), National Institute of Alcohol Abuse and Alcoholism (Grant No. R01AA027486 to R.M.W.), National Institute of Diabetes and Digestive and Kidney Diseases (Grant No. R01DK126827 and R01DK058185 to T.O.), and the Mayo Clinic Research Foundation (to R.M.W. and T.T.L.N.).

CONFLICT OF INTEREST
Drs Weinshilboum and Wang are co-founders of and stockholders in OneOme, LLC. All authors are or were affiliated with the Mayo Clinic.

DATA AVAILABILITY STATEMENT
The genotyping data for this study were deposited in Gene Expression Omnibus under accession number GSE23120. All other sequencing data were deposited under accession number GSE185941.

ORCID
Thanh Thanh L. Nguyen https://orcid.org/0000-0002-2281-6540
Duan Liu https://orcid.org/0000-0003-1065-246X
Huanyao Gao https://orcid.org/0000-0002-9441-9579
Liewei Wang https://orcid.org/0000-0003-3818-8531
Tamas Ordog https://orcid.org/0000-0002-3940-7284
Richard M. Weinshilboum https://orcid.org/0000-0002-4911-7985

REFERENCES
1. Tian B, Manley JL. Alternative polyadenylation of mRNA precursors. Nat Rev Mol Cell Biol. 2017;18:18-30.
2. Elkon R, Ugalde AP, Agami R. Alternative cleavage and polyadenylation: extent, regulation and function. Nat Rev Genet. 2013;14:496-506.
3. Berkovits BD, Mayr C. Alternative 3′UTRs act as scaffolds to regulate membrane protein localization. *Nature*. 2015;522:363-367.

4. Derti A, Garrett-Engele P, MacIsaac KD, et al. A quantitative atlas of polyadenylation in five mammals. *Genome Res.* 2012;22:1173-1183.

5. Gruber AJ, Zavolan M. Alternative cleavage and polyadenylation in health and disease. *Nat Rev Genet*. 2019;20:599-614.

6. Stacey SN, Sulem P, Jonasdottir A, et al. A germline variant in the TP53 polyadenylation signal confers cancer susceptibility. *Nat Genet*. 2011;43:1098-1103.

7. Xia Z, Donehower LA, Cooper TA, et al. Dynamic analyses of alternative polyadenylation from RNA-seq reveal a 3′-UTR landscape across seven tumour types. *Nat Commun*. 2014;5:5274.

8. Bennett CL, Brunkow ME, Ramsdell F, et al. A rare polyadenylation signal mutation of the FOXF3 gene (AAUAAA→AAUGAA) leads to the IPEX syndrome. *Immunogenetics*. 2001;53:435-439.

9. Graham RR, Kyogoku C, Sigurdsson S, et al. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. *Proc Natl Acad Sci U S A*. 2007;104:6758-6763.

10. Hoque M, Ji Z, Zheng D, et al. Analysis of alternative cleavage and polyadenylation by 3′ region extraction and deep sequencing. *Nat Methods*. 2013;10:133-139.

11. Cancer Genome Atlas Research Network, Weinstein JN, Collisson EA, et al. The cancer genome atlas Pan-cancer analysis project. *Nat Genet*. 2013;45:1113-1120.

12. GTEx Consortium. The genotype-tissue expression (GTEx) project. *Nat Genet*. 2013;45:580-585.

13. Shulman ED, Elkon R. Systematic identification of functional SNPs interrupting 3′UTR polyadenylation signals. *PLoS Genet*. 2020;16:e1008977.

14. Li L, Huang KL, Gao Y, et al. An atlas of alternative polyadenylation quantitative trait loci contributing to complex trait and disease heritability. *Nat Genet*. 2021;53:994-1005.

15. Sandberg R, Neilson JR, Sarma A, Sharp PA, Burge CB. Proliferating cells express mRNAs with shortened 3′ untranslated regions and fewer microRNA target sites. *Science*. 2008;320:1643-1647.

16. Ji Z, Lee JY, Pan Z, Jiang B, Tian B. Progressive lengthening of 3′ untranslated regions of mRNAs by alternative polyadenylation during mouse embryonic development. *Proc Natl Acad Sci U S A*. 2009;106:7028-7033.

17. Jia X, Yuan S, Wang Y, et al. The role of alternative polyadenylation in the antiviral innate immune response. *Nat Commun*. 2017;8:14605.

18. Akman BH, Can T, Erson-Bensan AE. Estrogen-induced up-regulation and 3′-UTR shortening of CDC6. *Nucleic Acids Res.* 2012;40:10679-10688.

19. Gensler LS. Glucocorticoids: complications to anticipate and prevent. *Neurohospitalist*. 2013;3:92-97.

20. Nguyen TTL, Gao H, Liu D, et al. Glucocorticoids unmask silent non-coding genetic risk variants for common diseases. *bioRxiv* 2021.2021.0017877. 2021.

21. Erson-Bensan AE. Alternative polyadenylation and RNA-binding proteins. *J Mol Endocrinol*. 2016;57:F29-F34.

22. Niu N, Qin Y, Fridley BL, et al. Radiation pharmacogenomics: a genome-wide association study to identify radiation response biomarkers using human lymphoblastoid cell lines. *Genome Res.* 2010;20:1482-1492.

23. Xie Z, Bailey A, Kuleshov MV, et al. Gene set knowledge discovery with Enrichr. *Curr Proteom*. 2021;1:e90.

24. Van Nostrand EL et al. A large-scale binding and functional map of human RNA-binding proteins. *Nature*. 2020;583:711-719.

25. Yu J, Liu SL. Emerging role of LY6E in virus–host interactions. *Viruses*. 2019;11:1020.

26. Zhao X, Zheng S, Chen D, et al. LY6E restricts entry of human coronaviruses, including currently pandemic SARS-CoV-2. *J Virol*. 2020;94:e00562-20.

27. Pfäender S, Mar KB, Michailidis E, et al. LY6E impairs coronavirus fusion and confers immune control of viral disease. *Nat Microbiol*. 2020;5:1330-1339.

28. Rebendenne A, Roy P, Bonaventure B, et al. Bidirectional genome-wide CRISPR screens reveal host factors regulating SARS-CoV-2, MERS-CoV and Seasonal HCoVs. *Nat Genet*. 2022;54:1090-1102.

29. Jenal M, Elkon R, Loayza-Puch F, et al. The poly(A)-binding protein nuclear 1 suppresses alternative cleavage and polyadenylation sites. *Cell*. 2012;149:538-553.

30. Masuda A, Takeda JI, Okuno T, et al. Position-specific binding of FUS to nascent RNA regulates mRNA length. *Genes Dev*. 2015;29:1045-1057.

31. Ben-Yehuda S, Dix I, Russell CS, McGarvey M, Beggs JD, Kupiec M. Genetic and physical interactions between factors involved in both cell cycle progression and premRNA splicing in *Saccharomyces cerevisiae*. *Genetics*. 2000;156:1503-1517.

32. Tanaka I, Chakraborty A, Saulnier O, et al. ZRANB2 and SYF2-mediated splicing programs converging on ECT2 are involved in breast cancer cell resistance to doxorubicin. *Nucleic Acids Res*. 2020;48:2676-2693.

33. Zagulski M, Kressler D, Becam AM, Rytka J, Herbert CJ. Mak5p, which is required for the maintenance of the M1 dsRNA virus, is encoded by the yeast ORF YBR142w and is involved in the biogenesis of the 60S subunit of the ribosome. *Mol Genet Genomics*. 2003;270:216-224.

34. Memet I, Doebele C, Sloan KE, Bohsack MT. The G-patch protein NF-kappaB-repressing factor mediates the recruitment of the exonuclease XRN2 and activation of the RNA helicase DHX15 in human ribosome biogenesis. *Nucleic Acids Res*. 2017;45:5359-5374.

35. Shiozawa Y, Malcovati L, Galli A, et al. Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia. *Nat Commun*. 2018;9:3649.

36. Li Q, Li X, Tang H, et al. NSUN2-mediated m5C methylation and METTL3/METTL14-mediated m6A methylation cooperatively enhance p21 translation. *J Cell Biochem*. 2017;118:2587-2598.

37. Ishmael FT, Fang X, Houser KR, et al. The human glucocorticoid receptor as an RNA-binding protein: global analysis of glucocorticoid receptor-associated transcripts and identification of a target RNA motif. *J Immunol*. 2011;186:1189-1198.

38. Cain DW, Cidlowski JA. Immune regulation by glucocorticoids. *Nat Rev Immunol*. 2017;17:233-247.

39. Carpenter S, Ricci EP, Mercier BC, Moore MJ, Fitzgerald KA. Post-transcriptional regulation of gene expression in innate immunity. *Nat Rev Immunol*. 2014;14:361-376.

40. Davis CA, Hitz BC, Sloan CA, et al. The encyclopedia of DNA elements (ENCODE): data portal update. *Nucleic Acids Res*. 2018;46:D794-D801.
GLUCOCORTICOIDS MEDIATE GLOBAL POLYADENYLATION

41. Mittleman BE, Pott S, Warland S, et al. Alternative polyadenylation mediates genetic regulation of gene expression. *Elife*. 2020;9.
42. MacArthur J, Bowler E, Cerezo M, et al. The new NHGRI-EBI catalog of published genome-wide association studies (GWAS catalog). *Nucleic Acids Res*. 2017;45:D896-D901.
43. Gagliano Taliun SA, VandeHaar P, Boughton AP, et al. Exploring and visualizing large-scale genetic associations by using PheWeb. *Nat Genet*. 2020;52:550-552.
44. Youssef J, Novosad SA, Winthrop KL. Infection risk and safety of corticosteroid use. *Rheum Dis Clin North Am*. 2016;42:157-176, ix-x.
45. Dubois-Camacho K, Ottum PA, Franco-Muñoz D, et al. Glucocorticosteroid therapy in inflammatory bowel diseases: from clinical practice to molecular biology. *World J Gastroenterol*. 2017;23:6628-6638.
46. Christiansen CF, Christensen S, Mehnert F, Cummings SR, Chapurlat RD, Sørensen HT. Glucocorticoid use and risk of atrial fibrillation or flutter: a population-based, case-control study. *Arch Intern Med*. 2009;169:1677-1683.
47. Szappanos D, Tschismarov R, Perlot T, et al. The RNA helicase DDX3X is an essential mediator of innate antimicrobial immunity. *PLoS Pathog*. 2018;14:e1007397.
48. Soulat D, Bürcstkümm T, Westermayer S, et al. The DEAD-box helicase DDX3X is a critical component of the TANK-binding kinase 1-dependent innate immune response. *EMBO J*. 2008;27:2135-2146.
49. Horckmans M, Bianchini M, Santovito D, et al. Pericardial adipose tissue regulates granulopoiesis, fibrosis, and cardiac function after myocardial infarction. *Circulation*. 2018;137:948-960.
50. RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid-19. *N Engl J Med*. 2021;384:693-704.

SUPPORTING INFORMATION
Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Nguyen TTL, Liu D, Gao H, et al. Glucocorticoids mediate transcriptome-wide alternative polyadenylation: Potential mechanistic and clinical implications. *Clin Transl Sci*. 2022;15:2758-2771. doi:10.1111/cts.13402